Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2025—Qiagen announced that the FDA has cleared its QIAstat-Dx meningitis/encephalitis panel for clinical use. The panel simultaneously analyzes several of the most common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis.
February 2025—Mainz Biomed announced an agreement with Quest Diagnostics to support commercialization of Mainz Biomed’s next-generation screening test for colorectal cancer, ColoAlert. Quest will provide clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States to develop data supporting FDA validation of the test. Mainz Biomed will provide Quest with the option to exercise semi-exclusive rights to provide testing services based on the test kit for an 18-month period, assuming the test’s approval by the FDA.
February 2025—Werfen announced FDA 510(k) clearance for the Aptiva antiphospholipid syndrome immunoglobulin G and immunoglobulin M reagents. These immunoassay reagents use Aptiva’s particle-based multianalyte technology for the semiquantitative determination of anticardiolipin and anti-beta 2 glycoprotein 1 IgG and IgM in human serum and aid in diagnosing primary and secondary APS, when used in conjunction with other laboratory and clinical findings.
February 2025—StatLab Medical Products announced it has reached an agreement to acquire Diapath (Martinengo, Italy), a manufacturer of histology and cytology products and equipment. The integration of Diapath, with its equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, the Middle East, Africa, and Latin America positions StatLab to expand its market access, according to a StatLab press statement.
February 2025—Sysmex America has signed an agreement with Sentinel Diagnostics that grants Canadian rights to distribute and service Sentinel Diagnostics SentiFIT 270 and 800 analyzers as part of a new fecal immunochemical test.
February 2025—Beckman Coulter Diagnostics announced the availability of research use only blood-based biomarker immunoassays intended to assess phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, and apolipoprotein ε4 biomarkers. These neurogenerative RUO assays are available for use on the DxI 9000 immunoassay analyzer. The GFAP, NfL, and APOE ε4 assays are also available for use on the Access 2 immunoassay analyzer.
February 2025—Adaptive Biotechnologies Corp. and NeoGenomics announced a multiyear exclusive strategic commercial collaboration that aims to advance minimal residual disease monitoring options for patients with select blood cancers.
Februrary 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test. The test can be used to aid clinicians in determining a therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The Genomadix Cube CYP2C19 system identifies the CYP2C19 *2, *3, and *17 alleles directly from buccal swabs in about an hour.
February 2025—Verichem Laboratories has announced the availability of multilevel clinical reference materials intended for the calibration and calibration verification of acetaminophen and salicylate assays on a wide array of diagnostic testing systems. The materials come in a ready-to-use, liquid-stable format that incorporates the serum-like reactivity of a protein-based matrix with the gravimetric accuracy of an absolute standard. The kit contains 5.0 mL of material at six concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains ethanol and lactate to determine the calibration verification of these assays.
February 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio. The blood test measures the ratio of phosphorylated tau protein (pTau217) to beta‑amyloid 1-42, two key biomarkers implicated in the neurodegenerative processes of Alzheimer’s disease. A blood-based IVD test that can quantify these biomarkers in plasma could provide a noninvasive, accessible, and earlier method of detecting Alzheimer’s-related pathology, potentially before clinical symptoms manifest, the company said in a statement.
